Clobetasol propionate is a very potent topical corticosteroid which is indicated for use in short courses for conditions which do not respond satisfactorily to less active steroids. It is indicated for use in steroid responsive dermatoses of the scalp such as: - Psoriasis - Recalcitrant dermatoses.
Dignitana, a world leader in medical scalp-cooling technology, announced that the FDA has granted the company’s de novo application to...
Clobetasol is a very potent topical corticosteroid indicated for adults, elderly and children over 1 year for the short term treatment only of more resistant inflammatory and pruritic manifestations of steroid responsive dermatoses unresponsive to less potent corticosteroids. These include the following: - Psoriasis (excluding widespread plaque psoriasis) - Recalcitrant dermatoses - Lichen planus - Discoid lupus erythematosus - Other skin conditions which do not respond satisfactorily to less potent steroids.
Clobetasol is a very potent topical corticosteroid indicated for adults, elderly and children over 1 year for the short term treatment only of more resistant inflammatory and pruritic manifestations of steroid responsive dermatoses unresponsive to less potent corticosteroids. These include the following: • Psoriasis (excluding widespread plaque psoriasis) • Recalcitrant dermatoses • Lichen planus • Discoid lupus erythematosus • Other skin conditions which do not respond satisfactorily to less potent steroids.
For the topical treatment of dermatoses of the scalp, such as psoriasis and seborrhoeic dermatitis, which are unresponsive to less potent corticosteroids.
The FDA has approved a supplemental New Drug Application for Sorilux (calcipotriene) Foam, from Stiefel/GSK. The sNDA expands the indication...
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx...
Regaine for Men Extra Strength Scalp Solution 5% w/v Cutaneous Solution is indicated for the treatment of alopecia androgenetica in men. Onset and degree of hair regrowth may be variable among users. Although trends in the data suggest that those users who are younger, who have been balding for a shorter period of time or who have a smaller area of baldness on the vertex are more likely to respond to Regaine for Men Extra Strength Scalp Solution 5% w/v Cutaneous Solution, individual responses cannot be predicted.
Pfizer has filed a new drug application in Japan to market the oral JAK3/TEC kinase inhibitor ritlecitinib for the treatment of alopecia areata.
For the topical treatment of psoriasis of the scalp.